Skip to content
DataLookout
Menu

FORWARD-FANCT07778836

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Start date changed from estimate of Oct 26, 2026 to Aug 5, 2026
    • Site details revised at 3 of 4 sites
  2. Notable Start date pushed from Aug 5, 2026 to Oct 26, 2026 Show 6 more changesShow less
    • Eligibility criteria shortened, about 7 words
    • Primary endpoints: details revised at 2 of 2 entries
    • Study sites: 3 to 4
    • Secondary endpoints: details revised at 1 of 1 entry
    • Publications: details revised at 20 of 26 entries
    • Study description expanded, about 3 words
  3. Minor Secondary endpoints: details revised at 1 of 1 entryv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from baseline in Upright Stability Score (USS) subscale E of modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)
Timeframe: Baseline, Weeks 12, 24, 36, 48, 72
Change from baseline in the total modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)
Timeframe: Baseline, Weeks 12, 24, 36, 48, 72

Secondary (1)

Change from baseline in the Clinical Global Impression-Severity (CGI-S) score at Week 72

Arms and interventions

NomlabofuspExperimental

Daily subcutaneous injection of nomlabofusp for 72 weeks

PlaceboPlacebo comparator

Daily subcutaneous injection of placebo for 72 weeks

Drugs: Nomlabofusp, Placebo

Sites

4 sites in 1 country